Thrombin-mediated activation of Factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis

被引:182
|
作者
VondemBorne, PAK
Bajzar, L
Meijers, JCM
Nesheim, ME
Bouma, BN
机构
[1] UNIV UTRECHT HOSP,DEPT HAEMATOL,NL-3508 GA UTRECHT,NETHERLANDS
[2] UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405
[3] QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA
[4] QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA
来源
JOURNAL OF CLINICAL INVESTIGATION | 1997年 / 99卷 / 10期
关键词
coagulation; fibrinolysis; Factor XI; thrombin; carboxypeptidase; COAGULATION FACTOR-XI; BLOOD-COAGULATION; PROTEIN-C; PLASMINOGEN-ACTIVATOR; CLOT LYSIS; PLASMA; CARBOXYPEPTIDASE; PURIFICATION; GENERATION; SYSTEM;
D O I
10.1172/JCI119412
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Recently, it has been shown that Factor XI can be activated by thrombin, and that Factor XIa significantly contributes to the generation of thrombin via the intrinsic pathway after the clot has been formed. This additional thrombin, generated inside the clot, was found to protect the clot from fibrinolysis. A plausible mechanism for this inhibitory effect of thrombin involves TAFI (thrombin-activatable fibrinolysis inhibitor, procarboxypeptidase B) which, upon activation, may inhibit fibrinolysis by removing carboxy-terminal lysines from fibrin. We studied the role of Factor XI and TAFI in fibrinolysis using a clot lysis assay. The lysis time was decreased two-fold when TAFI was absent, when TAFI activation was inhibited by anti-TAFI antibodies, or when activated TAFI was inhibited by the competitive inhibitor (2-guanidinoethylmercapto)succinic acid. Inhibition of either TAFI activation or Factor XIa exhibited equivalent profibrinolytic effects. In the absence of TAFI, no additional effect of anti-Factor XI was observed on the rate of clot lysis. We conclude that the mechanism of Factor XI-dependent inhibition of fibrinolysis is through the generation of thrombin via the intrinsic pathway, and is dependent upon TAFI. This pathway may play a role in determining the fate of in vivo formed clots.
引用
收藏
页码:2323 / 2327
页数:5
相关论文
共 50 条
  • [31] The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?
    Marx, P. F.
    Plug, T.
    Havik, S. R.
    Morgelin, M.
    Meijers, J. C. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 445 - 452
  • [32] Internalization of thrombin-activatable fibrinolysis inhibitor in keratinocytes by receptor-mediated endocytosis
    Verkleij, C. J. N.
    Reits, E. A. J.
    Plug, T.
    Marx, P. F.
    Meijers, J. C. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 : 33 - 33
  • [33] Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms
    Zhao, L
    Morser, J
    Bajzar, L
    Nesheim, M
    Nagashima, M
    THROMBOSIS AND HAEMOSTASIS, 1998, 80 (06) : 949 - 955
  • [34] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
    Eichinger, S
    Schönauer, V
    Weltermann, A
    Minar, E
    Bialonczyk, C
    Hirschl, M
    Schneider, B
    Quehenberger, P
    Kyrle, PA
    BLOOD, 2004, 103 (10) : 3773 - 3776
  • [35] Role of Thrombin-Activatable Fibrinolysis Inhibitor in Allergic Bronchial Asthma
    Fujiwara, Atsushi
    Taguchi, Osamu
    Takagi, Takehiro
    D'Alessandro-Gabazza, Corina N.
    Boveda-Ruiz, Daniel
    Toda, Masaaki
    Yasukawa, Atsushi
    Matsushima, Yuki
    Miyake, Yasushi
    Kobayashi, Hiroyasu
    Kobayashi, Tetsu
    Gil-Bernabe, Paloma
    Naito, Masahiro
    Yoshida, Masamichi
    Morser, John
    Takei, Yoshiyuki
    Gabazza, Esteban C.
    LUNG, 2012, 190 (02) : 189 - 198
  • [36] Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension
    Yaoita, Nobuhiro
    Satoh, Kimio
    Satoh, Taijyu
    Sugimura, Koichiro
    Tatebe, Shunsuke
    Yamamoto, Saori
    Aoki, Tatsuo
    Miura, Masanobu
    Miyata, Satoshi
    Kawamura, Takeshi
    Horiuchi, Hisanori
    Fukumoto, Yoshihiro
    Shimokawa, Hiroaki
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (06) : 1293 - +
  • [37] Isolation and characterization of a murine thrombin-activatable fibrinolysis inhibitor (TAFI).
    Conway, EM
    Ong, K
    Steiner-Mosonyi, M
    Bajzar, L
    Schuh, AC
    BLOOD, 1998, 92 (10) : 94B - 94B
  • [38] The role of thrombin-activatable fibrinolysis inhibitor in diabetic wound healing
    Verkleij, Chantal J. N.
    Roelofs, Joris J. T. H.
    Havik, Stefan R.
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS RESEARCH, 2010, 126 (05) : 442 - 446
  • [39] Deficiency of Thrombin-activatable Fibrinolysis Inhibitor Worsens Bronchial Asthma
    Takagi, T.
    Urawa, M.
    Naitou, M.
    Fujiwara, A.
    Ebihara, A.
    Kobayashi, T.
    Kobayashi, H.
    D'Alessandro-Gabazza, C. N.
    Gabazza, E. C.
    Taguchi, O.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [40] Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia
    Malyszko, J
    Malyszko, JS
    Hryszko, T
    Mysliwiec, M
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (06) : 2219 - 2221